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Primary cutaneous apocrine carcinoma (PCAC) is
a rare cutaneous adnexal tumor that presents a
diagnostic challenge, with histology and staining
mirroring those seen in mammary ductal carcinoma
and other adnexal neoplasms. We report the first
case, to our knowledge, of PCAC with in-transit
metastasis responding to primary radiotherapy as a
treatment. We also describe a case of PCAC treated
with axillary lymph node dissection, wide local
excision, and adjuvant radiotherapy. We hope this
review provides greater awareness of this neoplasm
in the differential diagnoses of metastatic breast
carcinoma, as the prognostic implications may differ
significantly.CASE 1
A 73-year-old white man with a medical history of
chronic lymphocytic leukemia presented with a
3-year history of a slow-growing, painless mass in
his left axilla with occasional serosanguinous
drainage. Courses of topical antibiotics, antifungals,
and topical steroids were ineffective. Physical
examination found numerous, indurated brightly
erythematous plaques and nodules in the axilla and
lateral left breast with nipple inversion (Fig 1).
Punch biopsy found dermal aggregates of large,
pleomorphic epithelioid cells with abundant
cytoplasm (Fig 2). Some cells displayed a signet-
ring appearance (Fig 3). Immunohistochemical
staining showed pancytokeratin, cytokeratin 7, gross
cystic disease fluid protein, and GATA3 positivity.
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m.factor, CDX2, and prostate-specific antigen were
negative. Estrogen receptor (ER), progesterone re-
ceptor (PR), and HER2/neu were negative. Given the
concern for metastasis from a primary breast or solid
organ malignancy, the patient underwent an exten-
sive workup including a full body positron emission
tomography scan, computed tomography scans,
serum tumor markers, and mammography, with no
other malignant foci identified. With the patient’s
comorbidities and extensive involvement, he was
treated with radiation therapy and showed a clinical
response (Fig 4). Unfortunately, the patient died of a
myocardial infarction 2 weeks after completion of
radiation therapy.
CASE 2
A 56-year-old white man presented with an
enlarging lesion in his left axilla that had been
present for 5 years. He was treated previously for a
presumed abscess with antibiotics for several weeks
with no resolution. On physical examination, a 3- 3
3-cm, erythematous-to-brown, firm plaque with
central nodularity was present. Punch biopsy found
similar findings to those in case 1 including a diffuse
infiltrate extending from the papillary dermis to the
subcutis, composed of cells with indistinct bordersJAAD Case Reports 2016;2:411-4.
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Fig 1. Primary cutaneous apocrine carcinoma. Case 1:
multiple, indurated brightly erythematous plaques and
nodules in the axilla and lateral left breast with nipple
inversion.
Fig 2. Dermal aggregates of large, pleomorphic epithelioid
cells with abundant cytoplasm. (Hematoxylin-eosin stain;
original magnification:34.)
Fig 3. Some cells displayed a signet-ring appearance.
(Hematoxylin-eosin stain; original magnification: 320.)
Fig 4. Case 1: after radiation therapy.
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Single-cell infiltration was noted in some
areas. Staining was positive for pancytokeratin,
p63, epithelial membrane antigen, and GATA3.
Stains for CD68, S-100, ER, and PR were negative.
The patient underwent a positron emission tomo-
graphyecomputed tomography scan, which showed
axillary lymph node involvement and was managed
with wide local excision and axillary lymph node
dissection. At the time of publication, he was
receiving ongoing adjuvant radiotherapy.DISCUSSION
PCAC is an extremely rare adnexal carcinoma that
occurs in middle-aged adults with approximately 50
cases reported in the literature. It arises in areas of
high apocrine gland density, including the axilla and
the anogenital region but has also been described
on the eyelid, ear, chest, and extremities. The
clinical findings vary, but PCAC typically presents
with erythematous, slow-growing, firm or cystic
nodules.
Table I. Staining patterns for IMDC versus PCAC
Stain IMDC PCAC
Cytokeratin 5,6 1/ 1 strong and diffuse
p63  /1
GATA3 1 1
Mammaglobin Strongly 1 Weakly 1
Adipophilin 1 strong and
diffuse

ER 1 1
PR /1 1/
AR 1 1
CEA  1
HER2/neu 1 
GCDFP-15 1 1
AR, Androgen receptor; CEA, carcinoembryonic antigen; IMDC,
intramammary ductal carcinoma; PCAC, primary cutaneous
apocrine carcinoma.
Data from refs.3-6,9,10
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mammary ductal carcinoma (IMDC), which is not
surprising, as mammary ducts are modified apocrine
sweat glands.1 Given the rarity of the tumor and lack
of studies, differentiating PCAC from cutaneous
breast metastasis is difficult to make on histologic
grounds and requires an in-depth knowledge of the
spectrum of various stains (Table I). One of the most
useful markers distinguishing primary cutaneous
adnexal tumors from breast metastasis is p63.
Unfortunately, p63 is not usually expressed in
PCAC but is helpful if present.2 Mammaglobin, a
well-known marker for IMDC that has stained with
strong positivity in prior studies, was also recently
observed to have weak positivity in PCAC and
IMDC.2
In addition to ruling out IMDC, a signet-ring cell
morphology was seen in case 1, raising concern for
metastatic stomach or colon carcinoma. This variant
has been reported in 6 other cases of PCAC3,4
and shows very similar staining characteristics
including positivity for epithelial membrane antigen,
carcinoembryonic antigen, gross cystic disease fluid
protein-15, and cytokeratins.
Aside from IMDC, the clinical and histopathologic
differential diagnoses include melanoma, lymphoma,
mycosis fungoides, extramammary Paget disease,
microcystic adnexal carcinoma, and apocrine hidra-
denocarcinoma. Given this broad differential
diagnosis, a thorough workup and history should be
performed to exclude these etiologies.
Although no standard of care exists due to its
rarity, most cases are managed with wide local
excision with suggested surgical margins of 1 to
2 cm.5 Fifty percent of patients have lymph node
metastasis at the time of diagnosis, but the decisionto perform sentinel lymph node biopsy is controver-
sial.5-7 It has been proposed that lesions greater
than 5 cm in diameter, those that are moderately or
poorly differentiated, or those that have clinically
involved lymph nodes should undergo lymph node
dissection.
Other options for treatment include Mohs
micrographic surgery in cosmetically sensitive areas,
adjuvant radiotherapy, and hormonal therapy. PCAC
responds poorly to conventional chemotherapy;
however, 1 case of adjuvant radiotherapy with
wide resection and tamoxifen therapy succeeded
in achieving remission.5 ER1 tumors have also
responded to tamoxifen, and HER2/neu1 tumors
have responded to combination therapy with
trastuzumab and lapatinib. A recent report of
lapatinib and capecitabine led to complete remission
in a patient with metastatic disease. The patient in
case 1 showed a clinical response to primary
radiation therapy, but complete histopathologic
response and sustained remission could not be
determined, as the patient died of unrelated causes.
Case 1 is the first reported case of primary radiation
therapy used to treat PCAC, and the second reported
case of PCAC showing response to radiation
therapy.5 Case 2 is continuing with ongoing adjuvant
radiotherapy after wide local excision and axillary
lymph node dissection.
Those with well-differentiated tumors tend to do
well and have a long-term remission (88%) if
surgery can be performed.8 Those with poorly
differentiated tumors have a worse prognosis.
There is a 28% 5-year local recurrence rate, with
the time of recurrence ranging from 5 months to
10 years. Despite the rarity of this tumor, we present
2 cases of PCAC highlighting their clinical, histologic,
and immunohistochemical profile. We hope that this
review provides greater awareness of this neoplasm
in the differential diagnoses of a metastatic breast
carcinoma, as the prognostic implications may differ
significantly.3REFERENCES
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